Page 42 - ARNM-1-1

Advances in Radiotherapy &

Nuclear Medicine

ORIGINAL RESEARCH ARTICLE
Concurrent intensity-modulated radiation

therapy and chemotherapy plus nimotuzumab
for locally advanced cervical squamous cell

cancer: A long-term follow-up result

Ang Qu, Ping Jiang, Panfeng Wang, Muyi Zhang, Xiuwen Deng, Weijuan Jiang,
Xu Li, Haitao Sun, Weishu Hua, and Junjie Wang*

Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, P.R. China

Abstract

The study aimed to evaluate the safety and efficacy of concurrent intensity-
modulated radiation therapy (IMRT) and chemotherapy plus nimotuzumab for
the treatment of locally advanced cervical squamous cell cancer (LACSCC). From
December 2013 to March 2017, 34 patients with stages IB2–IVA (FIGO 2009) cervical
squamous cell cancer were enrolled and received concurrent chemoradiotherapy
plus nimotuzumab. The prescription radiation dose was 50.4 Gy/28 F on the pelvic
field with or without extended-field radiation. An additional 30–36 Gy to Point A was
delivered with high-dose-rate brachytherapy. Cisplatin 40 mg/m and nimotuzumab
2
200 mg were infused intravenously weekly. The main and secondary outcome
*Corresponding authors: measures were toxicity evaluated using common terminology criteria for adverse
Junjie Wang events 4.03. and the outcome evaluated using response evaluation criteria in solid
(junjiewang@pku.edu.cn) tumors 1.1, respectively. The median follow-up duration was 66 months (13 – 98
Citation: Qu A, Jiang P, Wang P, months). All patients received 6 times of IMRT, brachytherapy, and nimotuzumab.
et al., 2023, Concurrent intensity- Among them, 24 received six cycles of chemotherapy, while 11 received 4–5 cycles.
modulated radiation therapy and
chemotherapy plus nimotuzumab No life-threatening toxicity was found. The incidence of acute Grade 3 bone marrow
for locally advanced cervical depression was 52.9% (18/34), and Grade 3 gastrointestinal tract reaction was 8.8%
squamous cell cancer: A long-term (3/34). The incidence of late toxicities was 58.8% (20/34), including vaginal-rectal
follow-up result. Adv Radiother
Nucl Med. fistula, intestinal obstruction, rectal hemorrhage, hematuria, vaginal stenosis, and
https://doi.org/10.36922/arnm.0408 paresthesia. About 90% of those were Grades 1–2. Complete response was achieved
Received: April 8, 2023 in 33 cases (97.1%). The 3-year disease-free survival, local progression-free survival
(LPFS), and overall survival rates were 79.4%, 91.2%, and 82.4%, respectively. The
Accepted: June 19, 2023 corresponding 5-year values were 79.4%, 91.2%, and 79.3%. In conclusion, concurrent
Published Online: July 5, 2023 IMRT and chemotherapy plus nimotuzumab may represent a well-tolerated and
Copyright: © 2023 Author(s). effective treatment regimen in patients with LACSCC.
This is an Open Access article
distributed under the terms of the
Creative Commons Attribution Keywords: Intensity-modulated radiation therapy; Locally advanced cervical squamous
License, permitting distribution, cell cancer; Nimotuzumab
and reproduction in any medium,
provided the original work is
properly cited.
Publisher’s Note: AccScience 1. Introduction
Publishing remains neutral with
regard to jurisdictional claims in [1]
published maps and institutional Cervical cancer ranks fourth in the incidence of female tumors , and 85% of cervical
[2]
affiliations. cancer cases occur in developing countries . External beam radiotherapy (EBRT)

Volume 1 Issue 1 (2023) 1 https://doi.org/10.36922/arnm.0408